secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2023-09-20T23:59:59+00:00
Accession:  0001193125-23-237762
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara announces FDA agreement on tab-cel comparability; BLA submission planned Q2 2024
--------------------------------------------------------------------------------

- FDA and Atara aligned on analytical comparability between manufacturing process versions of tab-cel.
- Alignment allows pooling of pivotal clinical trial data from different process versions for BLA.
- Atara expects to submit tab-cel BLA in Q2 2024, enabling inclusion of Phase 3 ALLELE data.
- Company also advancing U.S. partnership discussions for tab-cel commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312523237762/0001193125-23-237762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312523237762/d490760d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-237762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer